CorVent Medical announced today that it received FDA emergency use authorization (EUA) for primary critical care use of its Respond-19 ventilator.
Respond-19 is designed for the rapid expansion of critical care ventilation capacity by allowing hospitals to treat more patients suffering from acute respiratory distress syndrome (ARDS) amid the COVID-19 pandemic, according to a news release.
New York-based CorVent said the surge support system is optimized for long-term storage and cost-efficient healthcare preparedness. The company expects CE Mark approval to follow the EUA in early 2021.
CorVent’s Respond-19 ventilator combines ventilation features with a plug-and-play setup to streamline patient care, while its multi-stage antiviral filters offer infection control to protect patients and providers alike.
“Current critical care ventilators are not designed for periodic use, such as during global pandemics or disaster recovery. They require costly maintenance and additional time to deploy from long-term storage and are not optimized to prevent the transmission of respiratory illnesses,” CorVent CEO Richard Walsh said in the release. “Our team’s expertise in ventilator development and proven track record of bringing innovative products to market positions us to successfully address this pressing clinical need. We are proud that the RESPOND-19 ventilator expands access to lifesaving respiratory support, in a financially sustainable way, for hospitals and government agencies during this healthcare crisis and beyond.”